期刊文献+

应用ROC曲线下面积比较血清胰蛋白酶原-2与CA199对胰腺癌的诊断价值 被引量:2

Area Under ROC Curves in Evaluation and Comparison of Serum Trypsinogen-2 and CA199 in Diagnosis of Pancreatic Cancer
下载PDF
导出
摘要 目的比较血清胰蛋白酶原-2与CA199对胰腺癌诊断价值。方法选取中国人民解放军北京军区总医院、石景山医院诊为胰腺癌未经治疗的患者25例;对照组随机选取体检中心健康体检者35例。入组者均留取血清标本,采用ELISA法半定量检测血清胰蛋白酶原-2、CA199的含量。结果胰腺癌组患者血清胰蛋白酶原-2中位数为13.2μg/L,四分位间距为2.25~49.15μg/L,CA199中位数为211.6μg/L,四分位间距为42~326.7μg/L,对照组血清胰蛋白酶原-2中位数为0.8μg/L,四分位间距为0.6~1.2μg/L,CA199中位数为12.8μg/L,四分位间距为6.7~26.4μg/L。以1.85 ng/ml为临界值,此时血清胰蛋白酶原-2鉴别胰腺癌与正常人的敏感度和特异度分别为96%和91.4%,ROC曲线下的面积为0.988。以37.2 U/mL为临界值,CA199鉴别诊断胰腺癌与正常人的敏感度为88%,特异度为82.9%,ROC曲线下的面积为0.906,两者ROC曲线下面积差异无统计学意义。结论血清胰蛋白酶原-2与CA199诊断胰腺癌价值差异无统计学意义,可作为一种非侵入性筛选试验,为临床联合肿瘤标志物筛查胰腺癌提供了手段。 Objective To compare diagnostic value of serum trypsinogen-2 and CA199 in pancreatic cancer. Methods A total of 60 fresh serum samples were collected from the patients, including 25 cases of pancreatic cancer, 35 cases of normal control, detect the level of serum of trypsinogen-2 and CA199 by ELISA. Results The median level of serum trypsinogen-2 was 0.8 μg/L in the controls, interquartile Range was 0.6~1.2 μg/L, 13.2 μg/L and 2.25~49.15 μg/L in pancreatic cancer. The median level of serum CA199 was 12.8μg/L in the controls, interquartile Range was 6.7~26.4 μg/L, 211.6μg/L and 42~326.7μg/L in pancreatic cancer. The sensitivity and specificity for differentiation between pancreatic cancer and control group was 91.4%, 96%, respectively, the area under the ROC curve was 0.989. It was 88% and 82.9%, 0.906 for CA199. There was no statistically differences between the area of ROC curve of trypsinogen-2 and C199. Conclusion There was no statistically differences between the area of ROC curve of trypsinogen-2 and C199 in diagnosis of pancreatic cancer. As a non-invasive screening test, detection of serum trypsinogen-2 can be used to combined tumer markers in screen prophase pancreatic cancer.
出处 《继续医学教育》 2014年第10期32-35,共4页 Continuing Medical Education
关键词 胰腺癌 血清胰蛋白酶原-2 CA199 Pancreatic Cancer Serum Trypsinogen-2 CA199
  • 相关文献

参考文献18

  • 1Siegel R, Ma J, Zou Z, et al. Cancer statistics[J]. CA Cancer J Clin, 2014 ( 64 ) : 9-29.
  • 2Hedstrom J, Kemppainen E, Andersen J. et al. A comparison of serum trypsinogen-2 and trypsin-2- alphal-antitrypsin complex with lipase and amylase in the diagnosis and assessment of severity in the early phase of acute pancreatitis[J]. Am J Gastroenterol, 2001 (96): 424-30.
  • 3王喜文,董柏青,刘飞鹰.两相关诊断试验的ROC曲线下面积比较的SAS程序实现[J].数理医药学杂志,2010,23(6):671-674. 被引量:5
  • 4Hanley JA, McNeil BJ. A method of comparing the areas under a receiver operating characteristic curves derived from the same cases[J]. Radiology 1983(148): 839-843.
  • 5Long H, Li Q, Wang Y, et al. Effective combination gene therapy using Ceacam6-shRNA and the fusion suicide gene yCDgLy TK for pancreatic carcinoma in vitro[J]. Exp Ther Med, 2013, 5(1): 155-161.
  • 6Goonetilleke KS, Siriwardena AK. Systematic review of carbohy-drateantigen (CA199) as a biochemical marker in the diagnosis of pancreatic cancer[J]. Eur J Surg Oncol, 2007, 33 ( 3 ) : 266-270.
  • 7Miyata S, Miyagi Y, Miyagi E, et al. Stimulation of cellular growth and adhesion to fibronectin and vitronectin in culture and tumorigenicity in nude mice by overexpression of trypsinogen in human gastric cancer cells[J]. Clin Exp Metastases, 1995(16): 613-622.
  • 8Miyata S, Koshikawa N. Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of AIzheimer amyloid precursor protein in culture[J]. J Biochem, 1999(125): 1067-1076.
  • 9Hirahara F, Miyagi Y. Trypsinogen expression in human ovarian carcinomas[J]. Int J Cancer, 1995(63): 176-181.
  • 10Kawano N, Osawa H, Ito T, et al. Expression of gelatinase A,tissue inhibitor of metalloproteinases- 2,matrilysin,and trypsin (ogen) in lung neoplasms:an immunohistochemical study[J]. Hum Pathol, 1997, 28(5): 613-622.

二级参考文献37

  • 1母德清,彭淑牖,王国凤.P53蛋白和CA_(19-9)对合并慢性胰腺炎的胰腺癌细胞学诊断的辅助作用[J].中华肝胆外科杂志,2004,10(8):526-529. 被引量:4
  • 2曹红梅,唐钧.血清CA19-9在消化道疾病中的临床意义[J].放射免疫学杂志,2005,18(1):67-69. 被引量:13
  • 3石志良,秦锡虎,朱峰.良性胆道疾病患者CA19-9升高原因探讨[J].肝胆胰外科杂志,2006,18(5):303-304. 被引量:9
  • 4Qiu J, Luo P, Wasmund K, et al. Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines [ J]. Hybridoma, 1999, 18(1): 103-112.
  • 5Saluja SS, Sharma R, Pal S, et al. Differentiation between benign and malignant hilar obstructions using laboratory and radiological investigations: a prospective study [J]. HPB, 2007, 9(5): 373-382.
  • 6Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the pplication of CA19-9 in the differentiation of Panereaticobiliary cancer: analysis using a receiver operating characteristic curve [ J]. Am J Gastroenterol, 1999, 94(7) : 1941-1946.
  • 7Sheen-Chen SM, Sun CK, Liu YW, et al. Extremely elevated CA19- 9 in acute cholangitis [J]. Dig Dis Sci, 2007, 52( 11 ) : 3140-3142.
  • 8DeLong ER,DeLong DM,Clarke2Pearson DL.Comparing the areas under two or more correlated receiver operating characteristic curves:a nonparamet ric approach.Biomet rics,1988,44:837-845.
  • 9Hanley JA,McNeil BJ.A method of comparing the areas under a receiver operating characteristic curves derived from the same cases.Radiology 1983,148:839-843.
  • 10Jemal A, Siegel R, Ward E, et al. Cancer statieties, 2009[J]. CA Cancer J Clin, 2009, 59(4):225 -249.

共引文献27

同被引文献12

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部